Clustering-based COPD subtypes have distinct longitudinal outcomes and multi-omics biomarkers

BMJ Open Respir Res. 2022 Aug;9(1):e001182. doi: 10.1136/bmjresp-2021-001182.

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) can progress across several domains, complicating the identification of the determinants of disease progression. In our previous work, we applied k-means clustering to spirometric and chest radiological measures to identify four COPD-related subtypes: 'relatively resistant smokers (RRS)', 'mild upper lobe-predominant emphysema (ULE)', 'airway-predominant disease (AD)' and 'severe emphysema (SE)'. In the current study, we examined the associations of these subtypes to longitudinal COPD-related health measures as well as blood transcriptomic and plasma proteomic biomarkers.

Methods: We included 8266 non-Hispanic white and African-American smokers from the COPDGene study. We used linear regression to investigate cluster associations to 5-year prospective changes in spirometric and radiological measures and to gene expression and protein levels. We used Cox-proportional hazard test to test for cluster associations to prospective exacerbations, comorbidities and mortality.

Results: The RRS, ULE, AD and SE clusters represented 39%, 15%, 26% and 20% of the studied cohort at baseline, respectively. The SE cluster had the greatest 5-year FEV1 (forced expiratory volume in 1 s) and emphysema progression, and the highest risks of exacerbations, cardiovascular disease and mortality. The AD cluster had the highest diabetes risk. After adjustments, only the SE cluster had an elevated respiratory mortality risk, while the ULE, AD and SE clusters had elevated all-cause mortality risks. These clusters also demonstrated differential protein and gene expression biomarker associations, mostly related to inflammatory and immune processes.

Conclusion: COPD k-means subtypes demonstrate varying rates of disease progression, prospective comorbidities, mortality and associations to transcriptomic and proteomic biomarkers. These findings emphasise the clinical and biological relevance of these subtypes, which call for more study for translation into clinical practice.

Trail registration number: NCT00608764.

Keywords: COPD Exacerbations; COPD epidemiology; Emphysema; Imaging/CT MRI etc.

Publication types

  • Clinical Study
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Biomarkers
  • Cluster Analysis
  • Disease Progression
  • Emphysema* / complications
  • Humans
  • Prospective Studies
  • Proteomics
  • Pulmonary Disease, Chronic Obstructive* / complications
  • Pulmonary Emphysema* / complications
  • Pulmonary Emphysema* / diagnostic imaging
  • Tomography, X-Ray Computed

Substances

  • Biomarkers

Associated data

  • ClinicalTrials.gov/NCT00608764